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Summary 
Background and purpose: Hypoxia in tumours is known to cause resistance to 
conventional chemotherapeutic drugs. In contrast, little is known about the effects of 
hypoxia on targeted anti-cancer drugs. This study evaluated the effect of hypoxia on a 
series of clinically approved tyrosine kinase inhibitors (TKIs). Experimental 
approach: The effect of hypoxia (0.1% oxygen) on the activity of conventional 
cytotoxic drugs (5-fluorouracil, doxorubicin and vinblastine), the hypoxia activated 
pro-drug tirapazamine and 9 TKIs was determined in a panel of cell lines. Where 
hypoxia had a marked effect on chemosensitivity, western blot analysis to determine 
the effect of hypoxia on target expression and the effect of TKIs on cell signalling 
response under aerobic and hypoxic conditions was conducted. Key results: Three 
patterns of chemosensitivity were observed; resistance under hypoxia, equi-toxic 
activity against hypoxic and aerobic cells and preferential cytotoxicity to hypoxic 
cells. Significant hypoxia selectivity (independent of HIF1) was observed in the case 
of dasatinib and this correlated with the ability of dasatinib to inhibit phosphorylation 
of Src at tyrosine 530. Sorafenib was significantly less effective under hypoxic 
conditions but resistance did not correlate with hypoxia induced changes in 
RAF/MEK/ERK signalling. Conclusions and implications: Hypoxia influences the 
activity of TKIs but in contrast to conventional cytotoxic drugs, preferential activity 
against hypoxic cells can occur. The search for hypoxia targeted therapies has been 
long and fruitless and this study suggests that some clinically approved TKIs could 
preferentially target the hypoxic fraction of some tumour types.  
 
Keywords: hypoxia, tyrosine kinase inhibitors, Src, dasatinib, sorafenib, HIF1. 
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Introduction 
One of the characteristic features of solid tumours is the development of a 
microenvironment caused by a poor and inefficient vascular supply (Vaupel et al., 
2013). This physiological microenvironment is characterised by gradients of oxygen 
tension, nutrients, catabolites, cellular metabolites, cell proliferation and extracellular 
pH, all of which vary as a function of distance from a supporting blood vessel (Brown, 
2002; Vaupel, 2010). The presence of hypoxia has significant biological and 
therapeutic implications and hypoxia is established as a marker of poor prognosis in 
many cancer types (Vaupel, 2008). Resistance to conventional cytotoxic anti-cancer 
drugs has been extensively studied and whilst it is widely acknowledged that 
resistance is caused by hypoxia induced reduction in cell proliferation, other 
mechanisms are emerging (Brown, 2002; Rohwer et al., 2011; Brahimi-Horn et al., 
2012; Flamant et al., 2012; Onishi et al., 2012; Wu et al., 2012). In addition, the fact 
that hypoxic cells reside some distance away from blood vessels introduces drug 
delivery challenges and this further compounds the resistance of this population of 
cells (Heldin et al., 2004; Minchinton et al., 2006). The need to develop therapeutic 
approaches that target the hypoxic fraction was recognised many years ago and 
seminal studies by Sartorelli’s group showing that mitomycin C can target hypoxic 
cells (Kennedy et al., 1980; Sartorelli et al., 1994) led to the search for more effective 
hypoxia selective drugs. Hypoxia activated bioreductive prodrugs were actively 
pursued for many years and a number entered clinical trial (Wilson et al., 2011). 
Whilst elegant in concept, this approach has however proved extremely difficult to 
translate into clinical efficacy. Novel compounds are still being developed (McKeage 
et al., 2011; Weiss et al., 2011; Sun et al., 2012) and are in clinical trial but the fact 
remains that after 40 years of research and development, no hypoxia selective 
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bioreductive drugs have been approved for use in humans. The need to develop 
hypoxia selective drugs is even more prominent today as our understanding of the 
impact that hypoxia has on tumour biology and therapy increases.   
 
In contrast to conventional cytotoxic drugs, little or no information has been 
published concerning the effects of hypoxia on targeted therapeutics. Hypoxia is 
known to induce a plethora of biochemical changes, many of which are mediated by 
hypoxia inducible factors (Rohwer et al., 2011), and signal transduction pathways are 
influenced by hypoxia. This is exemplified by studies demonstrating that the 
expression of Src and phosphorylated Src proteins is elevated in hypoxic regions of 
pancreatic and cervical carcinoma xenografts (Pham et al., 2009). Furthermore, 
studies using the Bcl-2 inhibitor ABT-737 clearly demonstrate that targeted 
therapeutics can selectively kill hypoxic cells (Harrison et al., 2011; Klymenko et al., 
2011). The hypoxia selective activity of ABT-737 was attributed to hypoxia induced 
down regulation of myeloid cell leukaemia sequence-1, a protein that causes 
resistance to ABT-737 (Harrison et al., 2011). These studies demonstrate that hypoxia 
can modulate the activity of targeted anticancer drugs. The identification of clinically 
used tyrosine kinase inhibitors (TKIs) that are selectively toxic to hypoxic cells would 
be beneficial and would stimulate the design of novel combination strategies with 
drugs that preferentially target the aerobic fraction. In addition, resistance of hypoxic 
cells to TKIs would significantly influence the outcome of chemotherapy and this 
knowledge could help tailor chemotherapy to individuals who are most likely to 
benefit from these drugs. Given the importance of TKIs and other small molecule 
drugs in treating cancer, it is important to characterise the effects of hypoxia on the 
activity of targeted anti-cancer drugs (Filippi et al., 2011). The aim of this study was 
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to determine whether the response of a panel of cell lines to TKIs was influenced by 
hypoxia. Where differences between cellular response under aerobic and hypoxic 
conditions was obtained, additional studies were conducted to identify mechanisms of 
action.   
 
Materials and methods 
All standard cytotoxic drugs (Doxorubicin, vinblastine and 5-Fluorouracil), 
tirapazamine and tyrosine kinase inhibitors were prepared in DMSO, aliquoted and 
stored at -20
o
C until required for use. All cell culture reagents were obtained from 
Sigma Aldrich unless stated otherwise.  
 
Cell lines and culture conditions.  
As little is known about the effects of hypoxia on TKIs, the experimental design 
involved the evaluation of a number of TKIs against a panel of human cancer cell 
lines. As the TKIs evaluated had multiple mechanisms of action, it was not feasible to 
select cell lines that harboured specific mutations or activated pathways. In the initial 
phase of the project therefore, the cell lines used were DLD-1 human colorectal 
carcinoma, H460 and A549 human NSCLC cells, MDA-MB-231 human breast cancer 
and TK10 human renal cancer cells. An extended panel of cell lines was used to study 
the effects of hypoxia on the activity of dasatinib and these consisted of MDA-MB- 
468, MDA-MB-453, Hs578T, BT-20, T47D and MCF7, all of which are derived from 
human breast carcinomas. A549, H460, MDA-MB-231, MDA-MB-453, MCF7 and 
TK10 cells were obtained from the National Cancer Institute (Bethesda, USA). DLD-
1, Hs578T, BT20, T47D and MDA-MB-468 cells were purchased from the American 
Type Culture Collection (LGC Standards, London, UK).  
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Chemosensitivity studies 
Chemosensitivity under aerobic and hypoxic conditions was determined using the 
MTT assay as described previously (Phillips et al., 1992). Studies under hypoxia were 
performed in a Whitley H35 Hypoxystation (Don Whitley Scientific, UK). In this 
study, hypoxia was defined as 0.1% oxygen which is a physiologically relevant level 
of hypoxia that is associated with resistance to radiotherapy, the induction of HIF1 
activation and unfolded protein response (Wilson et al., 2011). It is also important to 
stress that these conditions are distinct from the majority of studies on bioreductive 
prodrugs where conditions of anoxia are typically used to evaluate compounds 
(Wilson et al., 2011). Initial validation of the MTT assay demonstrated that a linear 
relationship between cell number and absorbance was obtained under both hypoxic 
and aerobic conditions. Following a 24 hour exposure to 0.1% oxygen, linear 
regression analysis of the relationship between cell number and absorbance were 
identical to those obtained under aerobic conditions with the exception of A549 cells 
where r values of 4.97 x 10
5 
and 2.02 x 10
5
 were obtained under aerobic and hypoxic 
conditions respectively (data not shown). Even though the efficiency of MTT 
conversion to formazan was reduced in A549 cells under hypoxia, the relationship 
between cell number and absorbance is linear. To further confirm the suitability of the 
MTT assay for use under hypoxic conditions, cellular response was also determined 
by counting viable cells using a haemocytometer following continuous exposure to 
dasatinib.  
 
For chemosensitivity studies, cells were plated into 96 well plates at a density of 2 x 
10
3
 cells per well and incubated under aerobic or hypoxic conditions (0.1% oxygen) at 
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37
o
C in a CO2 enriched atmosphere overnight to allow cells to attach. The following 
day, media was removed from each well and replaced with media containing test 
compounds at a range of concentrations (8 wells per drug concentration). For hypoxia 
studies, drugs were diluted in media that had been conditioned under hypoxia for at 
least 24 hours prior to the start of the experiment. Following a 5 day incubation at 
37
o
C in a CO2 enriched atmosphere, MTT (0.5mg/ml) was immediately added to each 
well and incubated for 4 hours. Formazan crystals were dissolved in DMSO and the 
absorbance of the resulting solution was measured at 570nm. Cell survival was 
determined as the true absorbance of the treated wells divided by the controls and 
expressed as a percentage. The effect of hypoxia on the activity of drugs was 
expressed as the hypoxic cytotoxicity ratio (HCR), which is defined as the ratio of 
IC50 values under aerobic to hypoxic conditions.  
 
Antibodies and Western blot analysis.  
Antibodies to Src and p-Src (Src antibody sampler kit), EGFR and p-EGFR signalling 
pathways (Phosph-EGFR antibody sampler kit), Raf signalling (Raf family antibody 
sampler kit) and phospo ERK1/2 signalling (phosphor-ERK1/2 pathway sampler kit) 
were obtained from Cell Signalling Technology
® 
(Beverly, MA). Antibodies to β-
actin were obtained from Santa Cruz Biotechnology (USA). Secondary antibodies 
were horseradish peroxidase linked anti-mouse, or anti-rabbit. To determine the effect 
of selected tyrosine kinase inhibitors on cell signalling, cells were conditioned to 
hypoxia (0.1% oxygen) and normoxia for 24 hours prior to drug exposure. Cells were 
exposed to a range of drug concentrations for a further 24 hours prior to cell lysis and 
analysis by Western blotting. Images of immunoblots were digitally captured on 
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Molecular Imager FX and individual bands were quantified using Quantity One 
software (Biorad, Hemel Hempsted, UK).  
 
Role of HIF1 in the hypoxia selective activity of dasatinib.  
HIF1α protein expression was determined by Western blot analysis following the 
incubation of MDA-MB-231, MDA-MB-468 and MCF7 cells in 0.1% oxygen for 24 
hours. Western blot analysis was performed using a purified mouse anti-HIF1α 
antibody obtained from BD Biosciences (Oxford, UK) and band intensities from three 
independent experiments were quantified using Quantity One software (Biorad, 
Hemel Hempsted, UK). Under aerobic conditions, MDA-MB-231, MDA-MB-468 
and MCF7 cells were exposed to CoCl2 for 6 hours (150µM) or 24 hours (100µM) 
and HIFα expression determined as above. Once HIF1α expression had been 
confirmed, cells were exposed to dasatinib for one hour in the presence or absence of 
CoCl2 and cell survival determined using the MTT assay following a 5 day recovery 
period at 37
o
C.  
 
Quantitation of apoptosis following exposure of cells to dasatinib under aerobic 
and hypoxic conditions.  
MCF7, MDA-MB-468 and MDA-MB-231 cells were exposed to a range of dasatinib 
concentrations under aerobic and hypoxic conditions for 24 hours. Cells were 
harvested by trypsinisation and the percentage of cells undergoing apoptosis was 
determined by flow cytometry following Anexin-V-FLUOS staining (Roche, 
Penzberg, Germany) as described previously (Allison et al., 2009).   
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Results. 
Chemosensitivity studies.  
The response of cell lines to standard classical anti-cancer drugs (doxorubicin, 5-FU 
and vinblastine) and the hypoxia selective agent tirapazamine are presented in table 1 
and HCR values are presented graphically in figure 1. The classical anti-cancer drugs 
tested were generally more active against cells under aerobic conditions compared to 
hypoxic (0.1% oxygen) conditions with some exceptions. In the case of doxorubicin, 
activity against MDA-MB-231 cells was similar under aerobic and hypoxic conditions 
(IC50 = 0.42 ± 0.01 and 0.46 ± 0.05 µM respectively) and TK10 cells were marginally 
more responsive under hypoxic conditions (IC50 = 0.34 ± 0.03 and 0.26 ± 0.05 µM 
respectively). H460 cells were also equally sensitive to vinblastine under aerobic and 
hypoxic conditions (IC50 = 1.23 ± 0.03 and 1.36 ± 0.10 µM respectively). The 
magnitude of the effect of hypoxia on the cellular response to each drug was cell line 
dependent (figure 1). The hypoxia selective agent tirapazamine was preferentially 
active against all cell lines under hypoxic conditions although HCR values varied 
across the panel of cell lines (2.71 to 9.63 in MDA-MB-231 and A549 cells 
respectively, figure 1). Exposure to 0.1% oxygen induced a partial G1 arrest in the 
majority of cell lines within 24 to 48 hours (data not shown). These results are 
consistent with reduced cell growth observed under hypoxia (data not shown) and 
resistance to the conventional cytotoxic drugs evaluated in this study.  
 
The response of cell lines to TKIs under hypoxic and aerobic conditions is reported in 
table 1 and HCR values are presented in figure 2. Three patterns of response were 
observed: resistance under hypoxia (HCR < 1), equi-potent activity under aerobic and 
hypoxic conditions (HCR ≈ 1) and sensitivity under hypoxia (HCR >1). With the 
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exception of sorafenib, which was more resistant under hypoxia and imatinib which 
was equally active under aerobic and hypoxic conditions against all 5 cell lines, 
considerable heterogeneity in HCR values to individual drugs exist across the panel of 
cell lines tested (table 1, figure 2). This is illustrated most prominently in the case of 
dasatinib. Comparing the response of cells to dasatinib under aerobic and hypoxic 
conditions, A549 cells are resistant to dasatinib under hypoxic conditions (HCR = 
0.007) whereas MDA-MB-231 cells were significantly (p <0.01) more sensitive under 
hypoxia compared to oxygenated cells (HCR = 5.50). Haemocytometer counts of 
control and dasatinib treated MDA-MB-231 cells gave a HCR of 6.49 providing 
further verification that the MTT assay is appropriate for use under these experimental 
conditions. Other examples where all three patterns of response exist include erlotinib, 
sunitinib, nilotinib, and masatinib (figure 2).  In contrast to the conventional drugs 
tested, gefitinib, vandetinib and imatinib generally have equi-potent activity under 
hypoxic and aerobic conditions (table 1, figure 2).  
 
As dasatinib induced a significant increase in response under hypoxia in the MDA-
MB-231 breast cancer cell line and c-Src is a potential target in breast cancer 
(Tryfonopoulos et al., 2011), the effect of dasatinib against an extended panel of 
breast cancer cell lines was determined. The results are presented in table 2. As in the 
MDA-MB-231 cell line, dasatinib was significantly (p <0.01) more potent under 
hypoxia against MDA-MB-468 and MCF7 cell lines with HCR values of 5.23 and 
15.00 respectively. The response of MDA-MB-453 and Hs578T cells were similar 
under aerobic and hypoxic conditions with HCR values of 1.38 and 0.91 respectively. 
In contrast, T47D and BT20 cells were significantly (p <0.01) more resistant under 
hypoxic conditions with HCR values of 0.62 and 0.12 respectively (table 2). Whereas 
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basal levels of apoptosis in MDA-MB-468 cells were similar under aerobic and 
hypoxic conditions, dasatinib induced significantly (P < 0.01) more apoptosis across a 
range of doses in hypoxic cells (figure 3). This would account for the increased 
potency of dasatinib observed under hypoxia. Similar results were obtained for MDA-
MB-231 and MCF7 cells (data not shown).   
 
Based on the results, three compounds were selected for further studies designed to 
explore the mechanistic basis for hypoxia sensitivity or resistance. These were 
dasatinib, erlotinib and sorafenib.  
 
Influence of hypoxia on the expression of Src. 
The effect of 24 hour exposure to 0.1% oxygen on Src and p-Src levels in the panel of 
cell lines tested is presented in figure 4A. Under normoxic conditions, Src protein 
expression ranged from high (A549 and H460) to comparatively low (DLD-1, MDA-
MB-231 and TK10). Exposure to hypoxia increased levels of Src expression in DLD-
1, MDA MB 231, A549 and TK10 but had little effect of Src levels in H460 cells. 
Levels of pSrcY419 were influenced by exposure to hypoxia with increased 
expression observed in all cell lines except H460 cells (figure 4A). Expression of 
pSrcY530 decreased under hypoxia in all cells with the exception of DLD-1 cells 
where hypoxia had no obvious effect on pSrcY530 expression (figure 4A).   
 
Influence of dasatinib on Src signalling under aerobic and hypoxic conditions.  
The effect of dasatinib on Src and pSrc expression has been determined in hypoxia 
sensitive and resistant cells taken from both the initial panel of cell lines evaluated 
(figure 4B) and the extended panel of breast cancer lines (figure 5). In the initial panel 
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of cell lines, the effect of hypoxia on Src and p-Src expression 24 hours after 
treatment with a range of dasatinib concentrations in A549 (hypoxia resistant) and 
MDA-MB-231 (hypoxia sensitive) cells is presented in figure 4B. Under aerobic 
conditions, expression of pSrcY419 is reduced by dasatinib at doses as low as 5 nM 
(figure 4B). There was no significant difference in the inhibition of pSrcY419 under 
hypoxia and aerobic conditions in either cell line (figure 4B). A similar pattern of 
response was observed in the breast cancer panel of cells with no major differences in 
the ability of dasatinib to inhibit pSrcY419 expression under aerobic and hypoxic 
conditions (figure 5).  
 
In contrast, differences in the ability of dasatinib to inhibit the expression of 
pSrcY530 between aerobic and hypoxic cells were observed. In the hypoxia resistant 
A549 cells, pSrcY530 was effectively inhibited by dasatinib under aerobic conditions 
but not under hypoxic conditions (figure 4B). In the hypoxia sensitive MDA-MB-231 
cells, pSrcY530 expression was preferentially inhibited by dasatinib under hypoxic 
conditions (figure 4B). A similar pattern of response was observed in the extended 
panel breast cancer cell lines but the differential effects of dasatinib on pSrc530 
expression were less extreme (figure 5). These results suggest that the effects of 
dasatinib on pSrcY530 expression have a greater impact on cell response under 
hypoxic conditions than dephosphorylation of pSrcY419.  
 
Role of HIF1 in the hypoxia selective activity of dasatinib. 
The role of HIF1 in the hypoxic potentiation of dasatinib activity was determined in 
MCF7, MDA-MB-231 and MDA-MB-468 cells (figure 6). HIF1α expression was 
undetectable in all three cell lines under aerobic conditions. Following a 24 hour 
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exposure to 0.1% oxygen, a prominent increase in HIF1α levels was observed in the 
MCF7 and MDA-MB-468 cell lines whereas only a very minor increase in HIF1α was 
observed in MDA-MB-231 cells (figure 6A). Under aerobic conditions, treatment of 
cells with either 150µM or 100µM CoCl2 for 6 or 24 hours respectively induced 
HIF1α in all three cell lines (figure 6A). As treatment of cells with 150µM CoCl2 for 
6 hours induced HIF1α expression significantly in all cell lines, these conditions were 
used to determine the effect of HIF1α on cellular response to dasatinib. As illustrated 
in figure 6B, the response of cell lines to dasatinib in the presence of CoCl2 was 
reduced (MCF7) or equivalent (MDA-MB-231 and MDA-MB-468) to the response of 
cells treated with dasatinib alone. These results together with the very modest 
induction of HIF1α under hypoxic conditions in the MDA-MB-231 cells, suggests 
that the hypoxia selective activity of dasatinib is independent of HIF1.  
 
Influence of hypoxia and exposure to erlotinib on EGFR expression. 
Under aerobic conditions, EGFR protein expression was highest in TK10, MDA-MB-
231 and A549 cells (figure 7A). Under hypoxic conditions, there was a significant 
increase in EGFR levels in A549, DLD-1 and H460 whereas hypoxia had little effect 
in MDA-MB-231 and TK10 cells (figure 7A). The expression of phosphorylated 
EGFR (pEGFR Y1068) shows marked differences under hypoxia. In TK10 cells, p-
EGFR is strongly expressed under both aerobic and hypoxic conditions whereas in 
DLD-1 and A549 cells, there was a significant increase in p-EGFR under hypoxic 
conditions (figure 7A). No differences in the expression of pEGFR occurred between 
aerobic and hypoxic conditions in MDA-MB-231 cells and pEGFR was barely 
detectable in H460 cells under both aerobic and hypoxic conditions (figure 7A).  
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The effect of erlotinib on EGFR and pEGFR levels in TK10 (hypoxia resistant) and 
DLD-1 (marginally hypoxia sensitive) is presented in figure 7B. In the hypoxia 
resistant TK10 cell line, treatment with erlotinib for 24 hours did not affect the levels 
of EGFR but caused a dose dependent reduction in levels of pEGFR under both 
hypoxic and aerobic conditions (figure 7B). Under aerobic conditions levels of 
pEGFR were undetectable in cells treated with 60µM erlotinib whereas under hypoxic 
conditions, pEGFR was still detectable at 100µM (figure 7B). In DLD1 cells where 
the effects of hypoxia on the activity of erlotinib were marginally in favour of hypoxia 
selectivity (HCR = 1.36), no significant differences were observed in the ability of 
erlotinib to inhibit pEGFR were observed, despite the increased expression of EGFR 
under hypoxia (figure 7B).  
 
Relationship between cellular response to sorafenib and inhibition of 
RAF/MEK/ERK signalling pathways.  
Chemosensitivity studies demonstrated that sorafenib was the only drug that was less 
effective under hypoxic conditions across the panel of cell lines evaluated. HCR 
values ranged from 0.40 to 0.027 in DLD-1 and TK10 cells respectively (figure 2). 
The influence of hypoxia on the expression of RAF/MEK/ERK signalling pathways is 
presented in figure 8. Exposure to 0.1% oxygen for 24 hours affects the expression of 
p-cRaf, p-MEK1,2, p44/42 MAPK and p90RSK in a cell line dependent manner 
(figure 8) but these changes do not correlate with the emergence of resistance to 
sorafenib under hypoxia.   
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Discussion 
The resistance of hypoxic cells to the classical cytotoxic anti-cancer drugs has broadly 
been attributed to hypoxia induced changes in the cell cycle but more recent studies 
have demonstrated that other mechanisms exist (Brahimi-Horn et al., 2012; Flamant 
et al., 2012; Onishi et al., 2012; Wu et al., 2012). With the exception of doxorubicin 
that can be equally or more effective against certain cell types under hypoxic 
conditions (Teicher et al., 1981; Luk et al., 1990), the majority of cell lines used were 
resistant to classical cytotoxic drugs under hypoxic conditions (figure 1, table1). In 
contrast, the response of cells to TKIs under aerobic and hypoxic conditions varied in 
a cell line dependent manner with three main patterns of response observed (table1, 
figure 2). These were resistance under hypoxia, equitoxic effects under aerobic and 
hypoxic conditions and sensitivity under hypoxia. With the exception of sorafenib 
(which was resistant under hypoxia in all cell lines tested) and imatinib (which was 
equally active against hypoxic and aerobic cells), cellular response under hypoxia was 
strongly cell line dependent with all three patterns of response observed in many cases 
(figure 2). Responses to dasatinib for example ranged from hypoxia resistance in the 
case of A549 cells (HCR = 0.007) to hypoxia sensitivity in MDA-MB-231, MDA-
MB-468 and MCF7 cells (HCR = 5.50, 5.23 and 15.00 respectively, figure 2, table 2). 
Increased sensitivity to dasatinib under hypoxia was with increased cell kill as 
opposed to reduced cell growth, with a significant increase in apoptosis observed in 
MDA-MB-468, MDA-MB-231 and MCF7 (figure 3 and data not shown) cell lines.  
 
Dasatinib is an orally active inhibitor of Abl and Src kinases (Lombardo et al., 2004) 
and in broad agreement with previous studies (Pham et al., 2009), an increase in total 
Src expression was observed under hypoxic conditions in all cell lines with the 
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exception of H460 cells (figure 4A). Human c-Src signalling output is controlled post-
translationally by phosphorylation at Y530 and Y419 (Yeatman, 2004). 
Phosphorylation at Y530 inactivates c-Src whereas full activation requires 
phosphorylation at Y419. Under hypoxic conditions, cell line dependent changes in 
the expression of both pSrcY419 and pSrcY530 occurred (figure 4A) but no clear 
relationship between c-Src and p-Src and hypoxia resistance or sensitivity exists 
(figures 4 and 5). The ability of dasatinib treatment to dephosphorylate pSrcY530 did 
however correlate with cellular response and in the hypoxia sensitive cell lines, 
greater dephosphorylation of the inhibitory pSrcY530 occurred (figures 4B and 5) 
making cells more sensitive to dasatinib. In the hypoxia resistant cell lines, the 
dephosphorylation of pSrcY530 was reduced under hypoxia conditions (figures 4B 
and 5) thereby keeping c-Src in an inactive state. The ability of dasatinib to 
dephosphorylate pSrcY530 (rather than pSrcY419) contributes significantly to the 
differential response of cells to dasatinib. Further studies to determine the effect of 
dasatinib on Csk and Chk proteins that inactivate Src by phosphorylation at Y530 and 
the activating Src activator protein tyrosine phosphatase 1B (PTP1B) (Yeatman, 2004; 
Roskoski, 2005) are required. Hypoxic sensitisation of cells to dasatinib appears to be 
independent of HIF1 (figure 6). This is consistent with other studies showing that 
forced expression of HIF1 repressed Src signalling output by repressing transcription 
of PTP1B thereby conferring resistance to dasatinib (Suwaki et al., 2011). As cobalt 
chloride is known to stabilise HIF2α in aerobic conditions (Chan et al., 2002), our 
results (figure 6) also suggest that HIF2 is not involved in the hypoxic sensitisation of 
cells to dasatinib. Another potential mechanism that may influence response in 
normoxia and hypoxia is higher drug efflux capacity in hypoxic stem cell populations 
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(Challen et al., 2006). Further studies are required to verify these and other potential 
mechanisms of resistance.  
 
The impact of hypoxia on EGFR signalling pathways is of current interest (Wouters et 
al., 2013) and resistance to gefitinib under hypoxia has been reported in NSCLC cell 
lines that harbour both mutant and wild type EGFR (Minakata et al., 2012). The 
results of our study are broadly in agreement in that resistance to erlotinib and 
gefitinib was observed in some cell lines although HCR values close to 1 was seen in 
others (table 1, figure 2). The effect of hypoxia on the expression of EGFR and 
pEGFR varied depending on the cell line (figure 7A) with increased expression seen 
in some cells (eg DLD1) contrasting with no significant change in other cells (eg 
TK10). Increased expression of EGFR under hypoxia has been reported previously 
(Wang et al., 2010; Misra et al., 2012) but it is not clear why induction is cell line 
dependent. A trend between the ability of erlotinib to supress p-EGFR and response 
under aerobic and hypoxic conditions exists. In hypoxia resistant TK10 cells, reduced 
dephosphorylation of EGFR was observed under hypoxic conditions whereas little 
difference in the suppression of p-EGFR expression was observed in DLD-1 cells 
where erlotinib was equally active against aerobic and hypoxic cells (figure 7B). Our 
results further support the view that tumour hypoxia is an important factor that should 
be considered when treating patients (Minakata et al., 2012). Further work is required 
to identify the mechanisms responsible for the cell dependent nature of the hypoxia 
response to EGFR inhibitors.  
 
Sorafenib inhibits RAF/MEK/ERK signalling (Liu et al., 2006) but no obvious 
correlation was observed between resistance under hypoxia and the expression of 
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proteins involved in RAF/MEK/ERK signalling (figure 8). Sorafenib is however a 
multi-kinase inhibitor (Matsuda et al., 2011) and further studies are required to 
determine the role of RAF/MEK/ERK independent pathways in conferring hypoxia 
resistance. The resistance of cells under hypoxia is however potentially significant as 
sorafenib, by virtue of its anti-angiogenic properties, has been shown to induce 
hypoxia in renal cell carcinoma xenografts (Murakami et al., 2012). Recent studies 
have demonstrated that the development of a resistance to sorafenib is not due to 
permanent genetic changes or selection of resistant clones but is due to reversible 
changes that occur within the tumour or its microenvironment (Tang et al., 2010; 
Zhang et al., 2011). It is conceivable that the induction of hypoxia by sorafenib could 
generate a resistance phenotype, an effect that would be transient in nature depending 
upon oxygenation levels. Alternative dosing strategies including low dose 
metronomic (Tang et al., 2010) and high dose intermittent dosing (Wang et al., 2011) 
have shown improved efficacy in preclinical models but it is not clear whether this 
improved efficacy is due to reducing the induction of tumour hypoxia.  
 
In conclusion, the results of this study demonstrate that cell lines exposed to normoxic 
and hypoxic conditions can induce differential responses to clinically used TKIs. This 
includes preferential toxicity towards hypoxic cells as exemplified by dasatinib. In the 
context of the failure to develop therapies that selectively target hypoxic cells 
(Semenza, 2012), this study suggests that TKIs that show preferential toxicity towards 
hypoxic cells should be evaluated as potential hypoxia selective therapies. In the case 
of dasatinib, the activity of single agent dasatinib against solid tumours in the clinic 
has so far proved disappointing (Zhang et al., 2012), but further evaluation of 
dasatinib as a hypoxia selective drug could be valuable. In this context, combination 
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strategies using agents that target the aerobic fraction of tumours would be required 
and various preclinical studies have provided evidence that this is an attractive 
strategy (Montero et al., 2011; Raju et al., 2012). Whilst translating the results of this 
in vitro study into in vivo efficacy against hypoxic cells is challenging, this study 
suggests that certain TKIs should be re-evaluated as potential hypoxia selective 
therapies designed to overcome hypoxia induced drug resistance.  
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Table 1. Response of a panel of cell lines to conventional cytotoxic drugs, 
tirapazamine and targeted therapeutics under normoxic (N) and hypoxic (H) 
conditions. Cells were pre-incubated under normal and hypoxic (0.1% oxygen) 
conditions for 24 hours prior to a 96 hour exposure to each drug. Cell survival was 
determined using the MTT assay and results are expressed as IC50 values. The units 
are µM in all cases with the exception of those marked by an asterix where the units 
are nM. Each value represents the mean ± standard deviation of three independent 
experiments. Statistical analysis comparing response under hypoxia to aerobic 
conditions was performed using the students t-test and p values of < 0.05 and 0.01 are 
represented as 
+
 and 
++
 respectively.   
Drug A549 H460 MDA MB231 DLD1 TK10 
5FU (N) 2.28 ± 0.56 1.97 ± 1.27 14.61 ± 9.23 3.03 ± 0.59 41.35 ± 7.92 
5FU (H) 15.13 ± 3.72
++
 6.54 ± 1.13
++
 39.17 ± 5.21
++
 12.62 ± 3.02
++
 72.99 ± 25.38
+
 
Dox (N) 0.25 ± 0.04 0.023 ± 0.006 0.42 ± 0.01 0.074 ± 0.004 0.34 ± 0.03 
Dox (H) 1.00 ± 0.14
++
 0.066 ± 0.011
+
 0.46 ± 0.05 0.43 ± 0.05
++
 0.26 ± 0.05 
Vinblastine (N) 0.72 ± 0.05 1.23 ± 0.03 0.55 ± 0.06 2.47 ± 0.79 2.40 ± 0.17 
Vinblastine (H) 2.13 ± 0.69
++
 1.36 ± 0.10 0.85 ± 0.10 5.28 ± 0.44
+
 7.43 ± 1.43
++
 
Tirapazamine(N) 23.13 ± 3.41 22.85 ± 1.12 7.84 ± 0.86 15.91 ± 1.23 19.69 ± 2.54 
Tirapazamine(H) 2.40 ± 1.34
++
 2.53 ± 0.92
++
 2.89 ± 0.65
++
 2.95 ± 1.68
++
 3.38 ± 1.15
++
 
Sunitinib (N) 4.82 ± 0.31 3.73 ± 2.00 8.17 ± 1.13 2.85 ± 0.73 8.02 ± 0.63 
Sunitinib (H) 4.97 ± 0.42 2.54 ± 0.47 5.08 ± 0.49 0.50 ± 0.09
++
 5.92 ± 0.62 
Sorafenib (N) 2.74 ± 1.50 1.42 ± 0.13 0.51 ± 0.34 1.16 ± 0.53 0.25 ± 0.05 
Sorafenib (H) 21.63 ± 6.12
++
 5.49 ± 0.95
++
 2.10 ±1.38
++
 2.90 ± 0.77
+
 9.02 ± 3.05
++
 
Gefitinib (N) 23.32 ± 3.62 14.90 ± 1.11 10.62 ± 0.82 10.46 ± 1.94 0.97 ± 0.27 
Gefitinib (H) 16.69 ± 2.41 22.34 ± 2.12
++
 11.85 ± 0.78 7.22 ± 1.81
+
 9.10 ± 3.50
++
 
Masatinib (N) 18.17 ± 0.51 12.47 ± 1.52 8.39 ± 2.02 16.33 ± 3.10 14.72 ± 3.65 
Masatinib (H) 18.75 ± 2.81 18.47 ± 1.04
++
 12.93 ± 2.23
+
 5.34 ± 0.61
++
 10.40 ± 0.78 
Vandetinib (N) 7.60 ± 3.77 8.75 ± 0.78 8.12 ± 0.99 6.68 ± 1.90 2.35 ± 1.92 
Vandetinib (H) 8.07 ± 0.84 10.54 ± 0.37 5.56 ± 2.56
+
 4.25 ± 0.53
+
 1.82 ± 0.39 
Dasatinib (N) 0.17 ± 0.01 14.52 ± 1.48 33.0 ± 9.53* 2.25 ± 0.04 3.62 ± 1.08*  
Dasatinib (H) 23.92 ± 8.58
++
 11.18 ± 1.27 6.0 ± 4.35*
++
 25.09 ± 4.43
++
 12.17 ± 2.55*
++
 
Nilotinib (N) 7.61 ± 0.86 5.86 ± 1.89 2.81 ± 1.00 8.08 ± 2.64 1.12 ± 0.68 
Nilotinib (H) 9.98 ± 1.66 9.04 ± 0.94
+
 1.73 ± 1.02 5.39 ± 0.42 24.53 ± 0.99
++
 
Imatinib (N) 32.77 ± 0.85 23.76 ± 2.15 18.28 ± 0.68 21.58 ± 1.68 15.90 ± 3.17 
Imatinib (H) 33.28 ± 3.85 22.89 ± 3.10 19.69 ± 1.30 17.54 ± 1.20 18.96 ± 1.71 
Erlotinib (N) 3.74 ± 0.67 11.58 ± 0.85 15.70 ± 0.36 10.33 ± 0.65 4.71 ± 2.12 
Erlotinib (H) 33.83 ± 3.23
++
 29.58 ± 10.99
++
 20.11 ± 0.54
+
 7.56 ± 0.81
+
 47.25 ± 8.41
++
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Table 2. Response of a panel of breast carcinoma cell lines exposed to dasatinib 
under aerobic and hypoxic conditions for 96 hours. Each value represents the 
mean ± standard deviation for at least three independent experiments. Statistical 
analysis comparing response under hypoxia to aerobic conditions was performed 
using the students t-test and p values of < 0.05 and 0.01 are represented as 
+
 and 
++
 
respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line Aerobic IC50 (µM) Hypoxic IC50 (µM) HCR 
    
MCF7 0.18 ± 0.11 0.012 ± 0.007
++
 15.00 
MDA-MB-231 0.033 ± 0.009 0.006 ± 0.004
++
 5.50 
MDA-MB-468 16.58 ± 2.47 3.17 ± 1.70
++
 5.23 
MDA-MB-453 8.27 ± 3.36 5.97 ± 1.45 1.38 
Hs578T 0.044 ± 0.016 0.048 ± 0.013 0.91 
T47D 10.45 ± 2.98 16.85 ± 2.53
+
 0.62 
BT20 1.14 ± 0.59 9.63 ± 4.06
++
 0.12 
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Legends to figures 
Figure 1. Hypoxic Cytotoxicity Ratios (HCR) for 5-Fluorouracil, Doxorubicin, 
Vinblastine and Tirapazamine. The centre line represents a HCR of 1, which 
indicates that the response of cells under aerobic and hypoxia is equal. A HCR value 
greater than one indicates sensitivity under hypoxia. HCR of less than one indicates 
resistance under hypoxia. Each HCR is calculated from mean IC50 values obtained 
from three independent experiments (table 1). Experimental error in the form of 
standard deviations for IC50 values is presented in table 1.  
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Figure 2. Influence of hypoxia (0.1% oxygen) on the response of a panel of 
human cancer cells lines to tyrosine kinase inhibitors. Each HCR is calculated 
from mean IC50 values obtained from three independent experiments (table 1). 
Experimental error for IC50 values is presented in table 1. 
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Figure 3. Induction of cell death following the treatment of MDA-MB-468 cells 
with dasatinib. Cells were exposed to dasatinib under aerobic and hypoxic (0.1% 
oxygen) for 24 hours prior to analysis of early apoptotic cells (annexin V positive 
cells) and cells undergoing late apoptosis/necrosis (annexin V and propidium iodide 
[PI] positive cells). Each value represents the mean ± standard deviation for three 
independent experiments.  
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Figure 4. Influence of hypoxia and dasatinib on Src and p-Src levels.  The 
influence of a 24 hour exposure to 0.1% oxygen on the levels of Src, pSrcY419 and 
pSrcY530 in 5 cell lines is presented in panel A. In panel A, 231 refers to the MDA-
MB-231 cell line. The effect of dasatinib (in aerobic and hypoxic conditions) on Src, 
pSrcY419 and pSrcY530 in the hypoxia sensitive MDA-MB-231 and hypoxia 
resistant A549 cells is presented in panel B. In both cases, cells were exposed to 
dasatinib for 24 hours prior to harvesting for immunoblotting. Graphs show the 
quantification (± standard deviation) of Src (open bars), pSrc Y419 (solid bars) and 
pSrc Y530 (hatched bars) after normalisation to β-actin for a minimum of n = 3 
experiments.  
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Figure 5. Influence of hypoxia and dasatinib on Src and pSrc expression in a 
hypoxia sensitive and resistant breast cancer cell lines. Western blot analysis of 
Src, pSrcY419 and pSrcY530 following the treatment of hypoxia sensitive (MDA-
MB-468 and MCF7) and resistant (BT20) cells with dasatinib for 24 hours under 
aerobic and hypoxic conditions. Graphs show the quantification (± standard deviation) 
of Src (open bars), pSrcY419 (solid bars) and pSrcY530 (hatched bars) after 
normalisation to β-actin for a minimum of n = 3 experiments.  
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Figure 6. The role of HIF1 in the activity of dasatinib. Western blot analysis of the 
effect of hypoxia (24 hour exposure to 0.1% oxygen) and CoCl2 (6 hour exposure to 
150 µM and 24 hour exposure to 100 µM CoCl2 under aerobic conditions) on the 
expression of HIF1α is presented in panel A. The values presented below each lane 
represent the ratio of HIF1α to β-actin expression as determined by densitometry. The 
response of cells to dasatinib in the absence and presence of CoCl2 is presented in 
panel B. Cells were pre-treated with 150 µM CoCl2 for 6 hours prior to a one hour 
exposure to dasatinib and 150 µM CoCl2. Each value presented represents the mean ± 
standard deviation for three independent experiments. Statistical significance (P<0.01) 
between the control (no CoCl2) and CoCl2 treated groups is indicated by *. 
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Figure 7. Influence of hypoxia and erlotinib treatment on the expression of 
EGFR and pEGFR. The expression of EGFR and pEGFR (Y1068) under aerobic 
conditions and following 24 hours exposure to 0.1% oxygen is presented in panel A. 
The expression of EGFR and pEGFR in TK10 (hypoxia resistant, HCR=0.09) and 
DLD-1 cells (hypoxia sensitive, HCR=1.36) following 24 hours exposure to erlotinib 
(1 to 100µM) under aerobic and hypoxic conditions is presented in panel B. Graphs 
show the quantification (± standard deviation) of EGFR and p-EGFR after 
normalisation to β-actin for a minimum of n = 3 experiments.  
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Figure 8. Influence of hypoxia on Raf/Mek/Erk signalling. The expression of 
proteins involved in Raf/Mek/Erk signalling in 5 cell lines was determined following 
a 24 hour exposure to either aerobic or hypoxic (0.1% oxygen). The lane labelled 
MDA refers to the cell line MDA-MB-231. The values quoted directly under each 
blot represent quantitation of band intensities after normalisation to β-actin. The 
values presented represent the mean of 3 independent experiments but error bars have 
been omitted in the interests of clarity of presentation.  
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